Market Overview

Cantor Fitzgerald Initiates Coverage of Galena Biopharma with Buy Rating, $4 PT

Related GALE
Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients
Galena Biopharma Launches Zuplenz Oral Soluble Film

In a report published earlier today, Cantor Fitzgerald L.P. initiated coverage of Galena Biopharma Inc. (NASDAQ: GALE) with a Buy rating and a $4.00 price target.

Cantor Fitzgerald went on to say “Galena Biopharma is a development-stage company with a clinical candidate, NeuVax, in Phase III testing for prevention of recurrence of breast cancer in women at high risk for recurrence. The concept of using medication to lower recurrence risk is not new (tamoxifen, aromatase inhibitors), but the targeted patient population - low HER2 expressers - represents a new paradigm in treating patients. The addressable market is sizable (multi-billion), but Galena and NeuVax's path to Phase III trials has been anything but straightforward. Nonetheless, the shares are modestly valued and incremental news flow combined with NeuVax's market opportunity makes the shares attractive.”

Galena Biopharma Inc. closed on Friday at $1.29.

Latest Ratings for GALE

Sep 2015Raymond JamesInitiates Coverage onOutperform
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings


Related Articles (GALE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters